The KLF6 gene encodes the Krüppel-like factor 6, a transcription factor that has been individualized as a tumor-suppressor gene involved in the regulation of cell proliferation and differentiation. Recently, high frequency (42%) of KLF6 mutations have been reported in colorectal cancers (CRC) as in prostate cancers, astrocytic gliomas and hepatocellular carcinomas. The aims of the study was to confirm the frequency of KLF6 mutations in a larger series of CRC than that previously published by using DNA extracted from frozen tissue samples, which have been proved to generate less mutational artefact than that extracted from formalin-fixed paraffin-embedded tissue samples, in order to compare KLF6 mutation frequency with that of other common genetic alterations and to determine genotype–phenotype correlations. Amplification and direct sequencing of KLF6 exon 2 of 76 CRC and matched normal frozen tissues was performed. Polymorphisms were observed in 14 cases, among which two (T35T and S116S) had not already been reported. No KLF6 somatic mutation was observed. Our data suggest a minor role of KLF6 mutation in colorectal carcinogenesis and underline the fact that the validity of sequence informations obtained from DNA extracted from formalin-fixed tissues may be limited.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Scientific Reports Open Access 28 February 2018
Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for congenital heart disease (CHD)
BMC Medical Genetics Open Access 25 June 2007
Subscribe to Journal
Get full journal access for 1 year
only $2.38 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Andreyev HJ, Norman AR, Cunningham D, Oates JR and Clarke PA . (1998). J. Natl. Cancer Inst., 90, 675–684.
Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, Odin JA, Diehl JA, Germain D and Friedman SL . (2004). Cancer Res., 64, 3885–3891.
Bieker JJ . (2001). J. Biol. Chem., 276, 34355–34358.
Boyault S, Herault A, Balabaud C and Zucman-Rossi J . (2005). Hepatology, 41, 681–682; author reply 682–683.
Chen HK, Liu XQ, Lin J, Chen TY, Feng QS and Zeng YX . (2002). Ai Zheng, 21, 1047–1050.
Cho YG, Kim CJ, Park CH, Yang YM, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY and Park WS . (2005). Oncogene. 11 April [E-pub ahead of print].
Choi SW, Lee KJ, Bae YA, Min KO, Kwon MS, Kim KM and Rhyu MG . (2002). Clin. Cancer Res., 8, 2311–2322.
Duarte V, Gasparutto D, Jaquinod M and Cadet J . (2000). Nucleic Acids Res., 28, 1555–1563.
Feldman MY . (1973). Prog. Nucleic Acid Res. Mol. Biol., 13, 1–49.
Ferraz JM, Zinzindohoue F, Lecomte T, Cugnenc PH, Loriot MA, Beaune P, Stucker I, Berger A and Laurent-Puig P . (2004). Int. J. Cancer, 110, 183–187.
Goodman MF . (2002). Annu. Rev. Biochem., 71, 17–50.
Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O'Connell MJ, Witzig TE, Farr Jr GH, Goldberg RM and Thibodeau SN . (1999). J. Natl. Cancer Inst., 91, 1295–1303.
Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ and Thomas G . (1994). Gastroenterology, 106, 42–48.
Jeng YM and Hsu HC . (2003). Int. J. Cancer, 105, 625–629.
Kohler B, Wolter M, Blaschke B and Reifenberger G . (2004). Int. J. Cancer, 111, 644–645.
Koivisto PA, Hyytinen ER, Matikainen M, Tammela TL, Ikonen T and Schleutker J . (2004a). J. Urol., 172, 506–507.
Koivisto PA, Zhang X, Sallinen SL, Sallinen P, Helin HJ, Dong JT, Van Meir EG, Haapasalo H and Hyytinen ER . (2004b). Int. J. Cancer, 111, 642–643.
Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA and Friedman SL . (2004). Hepatology, 40, 1047–1052.
Montanini L, Bissola L and Finocchiaro G . (2004). Int. J. Cancer, 111, 640–641.
Muhlbauer KR, Grone HJ, Ernst T, Grone E, Tschada R, Hergenhahn M and Hollstein M . (2003). Br. J. Cancer, 89, 687–690.
Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, Zheng SL, Chang BL, Friedrichsen DM, Stanford JL, Ostrander EA, Chinnaiyan AM, Rubin MA, Xu J, Thibodeau SN, Friedman SL and Martignetti JA . (2005). Cancer Res., 65, 1213–1222.
Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA and Friedman SL . (2001). Science, 294, 2563–2566.
Peltomaki P and Vasen HF . (1997). Gastroenterology, 113, 1146–1158.
Quach N, Goodman MF and Shibata D . (2004). BMC Clin. Pathol., 4, 1.
Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S, Eng FJ, Arthur MJ, Martignetti JA and Friedman SL . (2004). Gastroenterology, 126, 1090–1103.
Smith CA, Baeten J and Taylor JS . (1998). J. Biol. Chem., 273, 21933–21940.
Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ and Wolf CR . (2002). Proc. Natl. Acad. Sci. USA, 99, 9433–9438.
Tindall KR and Kunkel TA . (1988). Biochemistry, 27, 6008–6013.
Vogelstein BFE, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM and Bos JL . (1988). N. Engl. J. Med., 319, 525–532.
Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson III AB and Hamilton SR . (2001). N. Engl. J. Med., 344, 1196–1206.
Williams C, Ponten F, Moberg C, Soderkvist P, Uhlen M, Ponten J, Sitbon G and Lundeberg J . (1999). Am. J. Pathol., 155, 1467–1471.
Wong C, DiCioccio RA, Allen HJ, Werness BA and Piver MS . (1998). Cancer Genet. Cytogenet., 107, 21–27.
Yngveson A, Williams C, Hjerpe A, Lundeberg J, Soderkvist P and Pershagen G . (1999). Cancer Epidemiol. Biomarkers Prev., 8, 433–438.
Zhou CZ, Peng ZH, Zhang F, Qiu GQ and He L . (2002). World J. Gastroenterol., 8, 668–673.
Le Ligue Nationale de Lutte Contre le Cancer.
About this article
Cite this article
Lièvre, A., Landi, B., Côté, JF. et al. Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. Oncogene 24, 7253–7256 (2005). https://doi.org/10.1038/sj.onc.1208867
- colorectal cancer
This article is cited by
Scientific Reports (2018)
Tumor Biology (2014)
Silencing of the transcription factor KLF6 by siRNA leads to cell cycle arrest and sensitizes cells to apoptosis induced by DNA damage
Cell Death & Differentiation (2008)
KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations
Modern Pathology (2008)
Current Colorectal Cancer Reports (2008)